143 related articles for article (PubMed ID: 18639380)
21. A review of the efficacy, tolerability and safety of sertindole in clinical trials.
Perquin L; Steinert T
CNS Drugs; 2004; 18 Suppl 2():19-30; discussion 41-3. PubMed ID: 15461313
[TBL] [Abstract][Full Text] [Related]
22. The European sertindole safety and exposure survey: a follow-up study of 8600 patients.
Peuskens J; Moore N; Azorin JM; Toumi M; Cochran J
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):804-11. PubMed ID: 17551996
[TBL] [Abstract][Full Text] [Related]
23. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
24. Marked elevation of creatine kinase with sertindole: a case report.
Oulis P; Koulouris GC; Konstantakopoulos G; Masdrakis VG
Pharmacopsychiatry; 2007 Nov; 40(6):295-6. PubMed ID: 18030658
[No Abstract] [Full Text] [Related]
25. Sertindole and impaired atrioventricular function, in the absence of Q-T prolongation: a case report.
Rizos EN; Leftheriotis D; Douzenis A; Chatziioannou S; Siafakas N; Nika S; Kremastinos D; Lykouras L
Psychiatry Clin Neurosci; 2010 Aug; 64(4):442. PubMed ID: 20653911
[No Abstract] [Full Text] [Related]
26. A review of the safety and tolerability of sertindole.
Hale AS
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
[TBL] [Abstract][Full Text] [Related]
27. Sertindole: efficacy and safety in schizophrenia.
Lindström E; Levander S
Expert Opin Pharmacother; 2006 Sep; 7(13):1825-34. PubMed ID: 16925508
[TBL] [Abstract][Full Text] [Related]
28. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
Peuskens J; Tanghøj P; Mittoux A;
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):425-33. PubMed ID: 18384186
[TBL] [Abstract][Full Text] [Related]
29. Two rapid-dose titrations of sertindole in patients with schizophrenia.
Sramek JJ; Mack RJ; Awni W; Hourani J; Jhee SS; Barto S; Cutler NR
J Clin Psychopharmacol; 1997 Oct; 17(5):419-22. PubMed ID: 9315993
[TBL] [Abstract][Full Text] [Related]
30. Sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile.
Brown GR; Radford JM
South Med J; 1997 Jul; 90(7):691-3. PubMed ID: 9225889
[TBL] [Abstract][Full Text] [Related]
31. Sertindole in schizophrenia: efficacy and safety issues.
Muscatello MR; Bruno A; Micali Bellinghieri P; Pandolfo G; Zoccali RA
Expert Opin Pharmacother; 2014 Sep; 15(13):1943-53. PubMed ID: 25084209
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sertindole in schizophrenia: a clinical review.
Zoccali RA; Bruno A; Muscatello MR
J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
[TBL] [Abstract][Full Text] [Related]
33. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
Kasper S; Möller HJ; Hale A
Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
[TBL] [Abstract][Full Text] [Related]
34. Emerging treatments in the management of schizophrenia - focus on sertindole.
Muscatello MR; Bruno A; Pandolfo G; Micò U; Settineri S; Zoccali R
Drug Des Devel Ther; 2010 Sep; 4():187-201. PubMed ID: 20856845
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of long QTc interval in methadone maintenance patients.
Fonseca F; Marti-Almor J; Pastor A; Cladellas M; Farré M; de la Torre R; Torrens M
Drug Alcohol Depend; 2009 Jan; 99(1-3):327-32. PubMed ID: 18774239
[TBL] [Abstract][Full Text] [Related]
36. Prolonged QTc intervals in medicated patients with schizophrenia.
Chong SA; Mythily ; Lum A; Goh HY; Chan YH
Hum Psychopharmacol; 2003 Dec; 18(8):647-9. PubMed ID: 14696025
[TBL] [Abstract][Full Text] [Related]
37. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts.
Thomsen MB; Volders PG; Stengl M; Spätjens RL; Beekman JD; Bischoff U; Kall MA; Frederiksen K; Matz J; Vos MA
J Pharmacol Exp Ther; 2003 Nov; 307(2):776-84. PubMed ID: 12966159
[TBL] [Abstract][Full Text] [Related]
38. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia.
Tay JK; Tan CH; Chong SA; Tan EC
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1297-302. PubMed ID: 17611010
[TBL] [Abstract][Full Text] [Related]
39. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009.
Xiang YT; Chiu HF; Ungvari GS; Correll CU; Lai KY; Wang CY; Si TM; Lee EH; He YL; Yang SY; Chong MY; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Tan CH; Shinfuku N
Hum Psychopharmacol; 2015 Mar; 30(2):94-9. PubMed ID: 25611192
[TBL] [Abstract][Full Text] [Related]
40. [Reduction of prolonged QTc-interval related risks in treatment with neuropharmacological drugs. Recommendations for clinical practice].
van de Kraats GB; Slob J; Tenback DE
Tijdschr Psychiatr; 2007; 49(1):43-7. PubMed ID: 17225205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
